Dietary amino acid taurine ameliorates liver injury in chronic hepatitis patients.
The effect of dietary amino acid taurine on the liver function of chronic hepatitis patients was investigated. The 24 chronic hepatitis patients with 2-5 times over normal activities of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) were selected and equally divided into taurine treatment and control groups. In taurine treatment group, each patient took 2 g taurine 3 times a day for three months, and then stopped treatment for 1 month. Patients taking placebo without taurine for 4 months served as a control group. ALT and AST activities and levels of cholesterol, triglyceride and thiobarbituric acid relative substances of serum plasma in the taurine group were all decreased at the end of three month treatment. The study suggested that dietary amino acid taurine may ameliorate liver injury for chronic hepatitis patients.
Hu
Y H
YH
Taoyuan Veteran Hospital, Taoyuan, Taiwan, China.
Lin
C L
CL
Huang
Y W
YW
Liu
P E
PE
Hwang
D-F
DF
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D001219:Aspartate Aminotransferases / Q000097:blood / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000473:pathology* / Q000821:virology; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000821:virology; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013654:Taurine / Q000008:administration & dosage*; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D010919:Placebos; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; D013654:Taurine; D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase